A new study published in the journal of Clinical Gastroenterology and Hepatology showed that despite using proton pump inhibitor (PPI), over one-third of Barrett’s esophagus (BE) patients who are asymptomatic show pathological reflux on pH monitoring. However, another third of individuals using standard-dose PPI had normal AET. A 9-fold higher incidence of neoplasia is linked to pathological reflux.

The patients with Barrett's esophagus who have abnormal acid exposure can be identified using esophageal function testing. By identifying pathological reflux, these tests offer useful risk classification, which allows for focused surveillance and early management to stop neoplastic change in this high-risk patient group. Thus, this study was set to ascertain how esophageal function testing m

See Full Page